Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Ermium Therapeutics, a France-based autoimmune disease therapy developer leveraging Paris Descartes University and CNRS research, closed a €6.3m ($6.9m) series A round yesterday backed by regional tech transfer office Satt Erganeo, biopharmaceutical company Domain Therapeutics, Kurma Partners and Idinvest. Founded in June 2019, Ermium aims to develop immunomodulators targeting the chemokine receptor CXCR4 to treat autoimmune diseases by inhibiting the production of inflammatory cytokines. Satt Erganeo, Kurma Partners and Domain Therapeutics co-founded the spinout together with researcher Jean-Philippe Herbeuval.